# Regorafenib in Combination With TAS-102 in Subjects With Metastatic Colorectal Cancer Who Have Progressed After Standard Therapy

> **NCT03305913** · PHASE1 · COMPLETED · sponsor: **AIO-Studien-gGmbH** · enrollment: 12 (actual)

## Conditions studied

- Pretreated Metastatic Colorectal Cancer

## Interventions

- **DRUG:** TAS 102
- **DRUG:** Regorafenib

## Key facts

- **NCT ID:** NCT03305913
- **Lead sponsor:** AIO-Studien-gGmbH
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-07-31
- **Primary completion:** 2018-10-31
- **Final completion:** 2019-04-26
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2021-03-26

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03305913

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03305913, "Regorafenib in Combination With TAS-102 in Subjects With Metastatic Colorectal Cancer Who Have Progressed After Standard Therapy". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03305913. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*